Dmitri MD - Fusion Pharmaceuticals Chief Officer
Executive
Dmitri MD is Chief Officer of Fusion Pharmaceuticals
| Age | 57 |
| Phone | 289 799 0891 |
| Web | https://www.fusionpharma.com |
Fusion Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.2334) % which means that it has lost $0.2334 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4711) %, meaning that it created substantial loss on money invested by shareholders. Fusion Pharmaceuticals' management efficiency ratios could be used to measure how well Fusion Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Fusion Pharmaceuticals currently holds 50.33 M in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest the company is not taking enough advantage from borrowing. Fusion Pharmaceuticals has a current ratio of 17.53, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Fusion Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Cathy Chang | Bioatla | N/A | |
| David MS | Ikena Oncology | N/A | |
| Alethia Young | Bicycle Therapeutics | 45 | |
| Christian JD | Harmony Biosciences Holdings | N/A | |
| Tamara LLM | Spero Therapeutics | 62 | |
| David CFA | Bicycle Therapeutics | N/A | |
| Nipun MBA | RAPT Therapeutics | 57 | |
| Eden Fucci | Passage Bio | N/A | |
| Kathleen Borthwick | Passage Bio | 48 | |
| JD Moriarty | Olema Pharmaceuticals | 56 | |
| Bin Zhang | Bioatla | N/A | |
| Christian Ulrich | Harmony Biosciences Holdings | N/A | |
| Jennifer Nicholson | RAPT Therapeutics | N/A | |
| Andrew Cutler | Relmada Therapeutics | N/A | |
| Michael Alonso | Bolt Biotherapeutics | N/A | |
| Gregory Fuest | Passage Bio | N/A | |
| Vladimir Vexler | Coherus BioSciences | 66 | |
| MSc MD | Bioatla | N/A | |
| Rebecca Cohen | Ikena Oncology | N/A | |
| Bob Rambo | NewAmsterdam Pharma | N/A | |
| MSc MBA | NewAmsterdam Pharma | 38 | |
Management Performance
| Return On Equity | -0.47 | |||
| Return On Asset | -0.23 |
Fusion Pharmaceuticals Leadership Team
Elected by the shareholders, the Fusion Pharmaceuticals' board of directors comprises two types of representatives: Fusion Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Fusion. The board's role is to monitor Fusion Pharmaceuticals' management team and ensure that shareholders' interests are well served. Fusion Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Fusion Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christopher Leamon, Chief Officer | ||
| John Valliant, CEO Founder | ||
| Mohit Rawat, President Officer | ||
| Eric Hoffman, Senior Development | ||
| Dmitri MD, Chief Officer | ||
| Maria Stahl, Chief Officer | ||
| Victor Paulus, VP Affairs | ||
| Cara Ferreira, Chief Staff | ||
| Joanne Schindler, Executive Development | ||
| Eric Burak, Chief Officer | ||
| John CPA, Chief Officer | ||
| Amanda Cray, Senior Communications |
Fusion Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Fusion Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.47 | |||
| Return On Asset | -0.23 | |||
| Operating Margin | (54.04) % | |||
| Current Valuation | 1.69 B | |||
| Shares Outstanding | 85.06 M | |||
| Shares Owned By Insiders | 0.46 % | |||
| Shares Owned By Institutions | 86.80 % | |||
| Number Of Shares Shorted | 3.06 M | |||
| Price To Book | 8.13 X | |||
| Price To Sales | 874.50 X |
Pair Trading with Fusion Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Fusion Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Fusion Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to AvalonBay Communities could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AvalonBay Communities when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AvalonBay Communities - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AvalonBay Communities to buy it.
The correlation of AvalonBay Communities is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AvalonBay Communities moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AvalonBay Communities moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for AvalonBay Communities can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Other Consideration for investing in Fusion Stock
If you are still planning to invest in Fusion Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Fusion Pharmaceuticals' history and understand the potential risks before investing.
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |